Artiva Biotherapeutics, Ownership
| ARTV Stock | 11.04 0.64 6.15% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Artiva |
Artiva Stock Ownership Analysis
About 21.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.33. Some equities with similar Price to Book (P/B) outperform the market in the long run. Artiva Biotherapeutics, recorded a loss per share of 2.48. The entity had not issued any dividends in recent years. For more info on Artiva Biotherapeutics, Common please contact Fred MD at 858 267 4467 or go to https://www.artivabio.com.Besides selling stocks to institutional investors, Artiva Biotherapeutics, also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Artiva Biotherapeutics,'s stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Artiva Biotherapeutics,'s strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Artiva Biotherapeutics, Quarterly Liabilities And Stockholders Equity |
|
About 21.0% of Artiva Biotherapeutics, Common are currently held by insiders. Unlike Artiva Biotherapeutics,'s institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Artiva Biotherapeutics,'s private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Artiva Biotherapeutics,'s insider trades
Artiva Biotherapeutics, Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Artiva Biotherapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Artiva Biotherapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Artiva Biotherapeutics, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Artiva Stock Analysis
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.